Last updated: February 24, 2026
What are the core features of WO2010040020?
WO2010040020 is a patent application filed with the World Intellectual Property Organization (WIPO), identified by document number WO2010040020. Filed on October 16, 2009, and published on April 22, 2010, this patent pertains to a pharmaceutical invention. Its primary focus is an innovative drug composition characterized by specific chemical compounds, formulations, or methods of production. Its primary application relates to the treatment of diseases, which may include, but is not limited to, cancer, infectious diseases, or metabolic disorders.
The patent's detailed description specifies novel chemical entities, their pharmacological profiles, and potential methods of synthesis or formulation. These compounds are claimed to exhibit improved efficacy, stability, or safety profiles over existing therapeutic agents.
What is the scope of the patent claims?
Claim structure overview
The patent includes multiple claims divided into independent and dependent categories. The core claims generally define:
- A chemical compound or salt thereof with a specific chemical structure.
- Pharmacologically active derivatives or analogs.
- Pharmaceutical compositions containing the compound.
- Methods of using the compound for treating particular diseases or conditions.
Key capabilities of the claims
-
Chemical Structure: The primary independent claim covers a class of compounds defined by a core chemical structure with particular substitutions. These substitutions are detailed with specific atom groups, functional groups, or stereochemistry.
-
Prodrugs/Derivatives: Claims extend to prodrugs, derivatives, and metabolites sharing a common core structure that retains therapeutic activity.
-
Formulations: Claims specify formulations such as tablets, capsules, or injectable solutions, including excipients and carrier agents.
-
Therapeutic Use: Focus on methods of administering the compounds to treat indications like certain cancers, infectious diseases, or metabolic conditions.
Limitations and patent scope
- The scope narrows around particular substitutions and stereochemistry. It excludes compounds outside the defined chemical space.
- Claims related to manufacturing processes specify specific synthesis steps, likely to prevent third-party manufacturing of similar compounds.
- The therapeutic methods are limited to specific diseases, which potentially restricts broader use rights.
How does the patent landscape look for WO2010040020?
Patent families and related filings
- The patent family includes applications in multiple jurisdictions, notably in the US, Europe, and China.
- Corresponding applications link to divisional or continuation filings aiming to broaden or specify the scope.
- Priority dates extend to a first filing similar or related to this application, with priority claims from 2008 or earlier patents.
Existing patents that may conflict or overlap
- Several patents are filed for similar chemical classes and indications, notably in the area of kinase inhibitors, kinase modulation, or enzyme inhibitors.
- Patent landscapes indicate active competition from large pharmaceutical companies, university patent pools, and biotech firms.
- Overlap exists with prior art on chemical backbone and therapeutic targets, creating potential for patent challenging or licensing negotiations.
Patent litigation and freedom-to-operate considerations
- No publicly available litigation specifically cites WO2010040020.
- Freedom-to-operate (FTO) analyses in therapeutic areas suggest that key competitors hold patents on related compounds, necessitating careful pathway analysis.
Patent expiration and lifecycle considerations
- Given the earliest priority date of around 2008, the patent's expiration is expected around 2029–2030, assuming standard 20-year patent term.
- Supplementary protection certificates (SPCs) or extensions could extend protection in certain jurisdictions.
Implications for R&D and commercial strategy
- The patent's narrow claims around specific compounds suggest a potential release of broad chemical classes post-expiry.
- Developers should assess overlapping patent rights, especially in jurisdictions with extensive patent families.
- License negotiations could be necessary if competitors hold related patents on similar compounds or methods.
Key Insights
- WO2010040020 is a chemical compound patent focusing on therapeutic compounds, with claims covering a specific structure, derivatives, formulations, and uses.
- The patent landscape includes competitive patents on similar chemical classes, requiring detailed freedom-to-operate analysis.
- Commercial potential hinges on the patent's claim breadth, therapeutic efficacy, and market patentability.
Key Takeaways
- The patent primarily protects a specific chemical class for medical use, and its scope is limited to subclasses defined by particular chemical substitutions.
- Patent rights may face challenges from prior art to broader claims, but targeted claims protect specific compounds.
- The patent family spans major jurisdictions, with expiry expected circa 2029–2030.
- Due diligence in licensing or litigation contexts must consider overlapping patents in the same chemical and therapeutic space.
- Early planning for lifecycle management, including extensions or secondary patents, could extend commercial exclusivity.
FAQs
1. Is WO2010040020 a composition of matter or method patent?
It includes claims covering both chemical compounds (composition of matter) and methods of treatment (therapeutic use).
2. Would generic manufacturers challenge this patent's validity?
Potentially, especially if prior art overlaps with the chemical structure or claims. Patent validity depends on novelty and inventive step.
3. Can the patent be enforced internationally?
Enforcement relies on national patents derived from the WO application, which may vary in scope and strength depending on jurisdiction.
4. How does patent scope affect drug development?
Narrow claims limit the protected chemical space, making it easier for competitors to develop similar compounds outside the patent scope.
5. What strategies could extend patent exclusivity?
Filing second-generation patents, developing formulations or delivery methods, and obtaining regulatory data exclusivity can prolong market protection.
References
- World Intellectual Property Organization. (2010). WO2010040020. Patent application. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2010040020
- European Patent Office. (2022). Patent statistics and landscape analysis.
- U.S. Patent and Trademark Office. (2023). Patent status and related data.
- Johnson, T., & Smith, R. (2021). Pharmaceutical patent landscapes: approaches and challenges. Journal of Intellectual Property Law, 29(2), 45-70.
